Literature DB >> 14737101

Identification of IGFBP-6 as a significantly downregulated gene by beta-catenin in desmoid tumors.

Hannelore Denys1, Ali Jadidizadeh, Saeid Amini Nik, Kim Van Dam, Stein Aerts, Benjamin A Alman, Jean-Jacques Cassiman, Sabine Tejpar.   

Abstract

Desmoid tumors (aggressive fibromatosis) are locally invasive soft tissue tumors in which beta-catenin-mediated TCF-3-dependent transcription is activated. To provide more insight into the pathophysiology of these tumors, expression profiles were generated using oligonucleotide arrays (Affymetrix). In total, 69 differentially expressed genes were identified in desmoids compared to normal fibroblasts (fascia) from the same patients. The differential expression of a selection of genes was confirmed using RT-PCR and Northern blotting. We further evaluated the insulin-like growth factor-binding protein 6 (IGFBP-6), a gene that was consistently downregulated in all desmoids tested. Promotor studies and electromobility shift assays revealed two functional beta-catenin/TCF-responsive elements in the human IGFBP-6 promoter. These findings suggest that IGFBP-6 is directly downregulated by the beta-catenin/TCF complex in desmoid tumors, and imply a role for the IGF axis in the proliferation of desmoid tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14737101     DOI: 10.1038/sj.onc.1207160

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases.

Authors:  Justin M M Cates; Jennifer O Black; Doha M Itani; John H Fasig; Vicki L Keedy; Kenneth R Hande; Brent W Whited; Kelly C Homlar; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Cheryl M Coffin
Journal:  Hum Pathol       Date:  2012-04-18       Impact factor: 3.466

Review 2.  Scar management in burn injuries using drug delivery and molecular signaling: Current treatments and future directions.

Authors:  Saeid Amini-Nik; Yusef Yousuf; Marc G Jeschke
Journal:  Adv Drug Deliv Rev       Date:  2017-07-27       Impact factor: 15.470

3.  Recent insights into the actions of IGFBP-6.

Authors:  Leon A Bach
Journal:  J Cell Commun Signal       Date:  2015-03-26       Impact factor: 5.782

4.  Molecular mechanisms and treatment strategies for Dupuytren's disease.

Authors:  David B O'Gorman; Linda Vi; Bing Siang Gan
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

5.  Reciprocal Negative Regulation between the Guanine Nucleotide Exchange Factor C3G and β-Catenin.

Authors:  Kunal Dayma; Anesh Ramadhas; Kotagiri Sasikumar; Vegesna Radha
Journal:  Genes Cancer       Date:  2012-09

6.  Clinicopathological significance of increased ZIC1 expression in human endometrial cancer.

Authors:  Xing Gu; Qin Liu; Ning Yang; Jian-Fang Shen; Xue-Gang Zhang; Fang Cao; Hou-Zhong Ding
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-12-16

7.  Extra-abdominal desmoid tumors associated with familial adenomatous polyposis.

Authors:  George T Calvert; Michael J Monument; Randall W Burt; Kevin B Jones; R Lor Randall
Journal:  Sarcoma       Date:  2012-06-03

8.  β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.

Authors:  Chiara Colombo; Antonino Belfiore; Nicholas Paielli; Loris De Cecco; Silvana Canevari; Erik Laurini; Maurizio Fermeglia; Sabrina Pricl; Paolo Verderio; Stefano Bottelli; Marco Fiore; Silvia Stacchiotti; Elena Palassini; Alessandro Gronchi; Silvana Pilotti; Federica Perrone
Journal:  Mol Oncol       Date:  2017-09-29       Impact factor: 6.603

9.  Gene expression profiling in familial adenomatous polyposis adenomas and desmoid disease.

Authors:  Nikola A Bowden; Amanda Croft; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2007-06-15       Impact factor: 2.857

10.  A phase 1 trial of xentuzumab, an IGF-neutralizing antibody, in Japanese patients with advanced solid tumors.

Authors:  Toshihiko Doi; Yasutoshi Kuboki; Yoichi Naito; Masahiro Ishida; Tetsuya Tanaka; Yoshito Takeuchi
Journal:  Cancer Sci       Date:  2022-01-13       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.